PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

CYPROTERONE ACETATE (CPA) IN THE TREATMENT OF ADVANCED PROSTATIC CANCER
Article published in Urologia Polska 1997/50/1.

authors

Leszek Jeromin, Marek Sosnowski, Marek Lipiński
Klinika Urologii Instytutu Chirurgii AM w Łodzi
Kierownik Kliniki: prof. dr hab. med. Z. Jeromin
Dyrektor Instytutu: prof. dr hab. med. A. Sołtysiak

keywords

prostate prostatic carcinoma treatment cyproterone acetate

summary

Objective. The authors present their own experience in the treatment of prostatic cancer
patients in stages C and D by cyproterone acetate (CPA).
Material and method. 42 previously untreated patients were observed in the period of
6 to 30 months. In 24 patients the treatment with 200 mg CPA per day was introduced
and in 18 patients 100 mg CPA per day was administered after castration. The following
control investigation was performed to assess final therapeutic effect: USG,bone scan,
X-ray, PSA and hormonal serum levels.
Results. Clinical improvement, regresion of prostatic cancer and metastasis were
observed. PSA and testosterone levels were systematically reduced and prolactin levels
increased considerably in the period of 3 to 6 months. CPA was badly tolerated in one
patient and the treatment was discontinuated. 3 out of 6 patient with the progression of
disease died despite the change of treatment. In 90% of patients no important side effects
were observed beside impotence.

references

  1. [1] Barradell, Z. B., Faulds, D.: Cyproterone?A review of its pharmacology and thera-
  2. peutic efficacy in prostete cancer. Drugs and Aging, July 1994, 5, 1
  3. [2] Gillet, D. A., Chedwick, D., Gingell, J. C, Boyle, P., Fellows, G., Peeling, B.:
  4. A randomised control trial of the LH-RH analogue Zoladex versus Cyproterone ece-
  5. tate versus the Combination of the two. AUA 86 Annual meeting June 2-6 1991,
  6. Toronto. Abstracts. J. Urol. Supl, 1991, 145, 317
  7. [3] Goldenberg, S. Z., Gleave, M. E.: Current perspectives on the expanding role of
  8. Androcur. Pharmalibri, Montreal-Chicago, 1994
  9. [4] Goldenberg, S. Z., Bruchovsky, N., Rennie P. S., Coppin, C: The Combination of
  10. Cyproterone acetate and low dose Diethylstilboestrol in the treatment of adwanced
  11. prostatic carcinoma. J. Urol., 1988, 140, 1460
  12. [5] Isurugi, K., Fukutani, K.., Ishida, H., Hosoi, Y.: Endocrine effects of Cyproterone
  13. acetate in patients with prostatic cancer. J. Urol., 1980, 123, 180
  14. [6] Jeromin, Z.: Testosterone and prolactin levels in the serum patients with carcino-
  15. ma of the prostate treated yarious doses of Fostrolin and Bromocriptine. Int. Urol.
  16. Nephrol., 1982, 14, 51
  17. [7] Namer, M., Frenay, M., Francois, E., Chevallier, D., Quintens, H.: Les antiandro-
  18. genes. Cancer de la prostste. Cours superieur francophone de cancerologie. Direc-
  19. teurs du cours M. Namer, J. Toubol. I.CI. -Pharma, Paris, 1991, 85
  20. [8] Neumann, F., Redlmaigr, A., Bormacher, K..: Hormonal treatment of adranced
  21. prostate cancer. Diesbach-Yerleg, Berlin 1989
  22. [9] Parys, B. T., Hamid, S., Thomson, G. N.: Severe hepatocellular dysfunction fol-
  23. lowing Cyproterone acetate therapy. Brit. J. Urol., 1991, 67, 312
  24. [10] Tunn, U. W.: Cyproterone acetate in the management of prostatic cancer. Thera-
  25. peutic progress in urological cancers. Alein R. Ziss Inc. Paris 1989, p. 105-110.
  26. Editors G. P. Murphy and S. Khoury.
  27. [11] De Voogt, H. J., Smith, P. FL, Pavone-Macaluso, M., De Pauw, M., Suciu, S.: Car-
  28. diovascular side effects of Diethylstilboestrol, Cryptoterone ecetate, Medroxypro-
  29. gesterone acetate and Estramustine phosphate used for the treatment of advanced
  30. prostatic cancer. Results from European Organization for Research on Treatment
  31. of Cancer Trisls 30761 and 30762. J. Urol, 1986, 135, 303